Global Neuroblastoma Treatment Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Description

According to our (Global Info Research) latest study, the global Neuroblastoma Treatment Drugs market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The market for neuroblastoma treatment drugs is showing steady growth, benefiting from advances in medical technology and research. The market size is gradually expanding, with drug sales increasing year by year. These drugs have specific uses in neuroblastoma patients, primarily aiming to reduce tumor volume, alleviate symptoms, and enhance survival rates by targeting tumor cells. Future developments may involve more personalized treatment approaches, combining targeted therapies and immunotherapies to improve efficacy while minimizing adverse drug reactions.

The Global Info Research report includes an overview of the development of the Neuroblastoma Treatment Drugs industry chain, the market status of Hospital (Cyclophosphamide, Dinutuximab), Clinic (Cyclophosphamide, Dinutuximab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neuroblastoma Treatment Drugs.

Regionally, the report analyzes the Neuroblastoma Treatment Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neuroblastoma Treatment Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Neuroblastoma Treatment Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neuroblastoma Treatment Drugs industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Cyclophosphamide, Dinutuximab).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neuroblastoma Treatment Drugs market.

Regional Analysis: The report involves examining the Neuroblastoma Treatment Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neuroblastoma Treatment Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Neuroblastoma Treatment Drugs:
Company Analysis: Report covers individual Neuroblastoma Treatment Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neuroblastoma Treatment Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

Technology Analysis: Report covers specific technologies relevant to Neuroblastoma Treatment Drugs. It assesses the current state, advancements, and potential future developments in Neuroblastoma Treatment Drugs areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neuroblastoma Treatment Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Neuroblastoma Treatment Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
    Cyclophosphamide
    Dinutuximab
    Naxitamab
    Doxorubicin Hydrochloride
    Vincristine Sulfate
    Other

Market segment by Application
    Hospital
    Clinic
    Other

Major players covered
    United Therapeutics
    Y-mAbs Therapeutics
    EUSA Pharma
    ANI Pharmaceuticals
    Baxter Healthcare
    Ingenus Pharmaceuticals
    Pfizer
    Hikma Pharmaceuticals
    Teva Pharmaceuticals

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroblastoma Treatment Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neuroblastoma Treatment Drugs, with price, sales, revenue and global market share of Neuroblastoma Treatment Drugs from 2019 to 2024.
Chapter 3, the Neuroblastoma Treatment Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroblastoma Treatment Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Neuroblastoma Treatment Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neuroblastoma Treatment Drugs.
Chapter 14 and 15, to describe Neuroblastoma Treatment Drugs sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Neuroblastoma Treatment Drugs
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Neuroblastoma Treatment Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Cyclophosphamide
        1.3.3 Dinutuximab
        1.3.4 Naxitamab
        1.3.5 Doxorubicin Hydrochloride
        1.3.6 Vincristine Sulfate
        1.3.7 Other
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Neuroblastoma Treatment Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Clinic
        1.4.4 Other
    1.5 Global Neuroblastoma Treatment Drugs Market Size & Forecast
        1.5.1 Global Neuroblastoma Treatment Drugs Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Neuroblastoma Treatment Drugs Sales Quantity (2019-2030)
        1.5.3 Global Neuroblastoma Treatment Drugs Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 United Therapeutics
        2.1.1 United Therapeutics Details
        2.1.2 United Therapeutics Major Business
        2.1.3 United Therapeutics Neuroblastoma Treatment Drugs Product and Services
        2.1.4 United Therapeutics Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 United Therapeutics Recent Developments/Updates
    2.2 Y-mAbs Therapeutics
        2.2.1 Y-mAbs Therapeutics Details
        2.2.2 Y-mAbs Therapeutics Major Business
        2.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
        2.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Y-mAbs Therapeutics Recent Developments/Updates
    2.3 EUSA Pharma
        2.3.1 EUSA Pharma Details
        2.3.2 EUSA Pharma Major Business
        2.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
        2.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 EUSA Pharma Recent Developments/Updates
    2.4 ANI Pharmaceuticals
        2.4.1 ANI Pharmaceuticals Details
        2.4.2 ANI Pharmaceuticals Major Business
        2.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
        2.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 ANI Pharmaceuticals Recent Developments/Updates
    2.5 Baxter Healthcare
        2.5.1 Baxter Healthcare Details
        2.5.2 Baxter Healthcare Major Business
        2.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
        2.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Baxter Healthcare Recent Developments/Updates
    2.6 Ingenus Pharmaceuticals
        2.6.1 Ingenus Pharmaceuticals Details
        2.6.2 Ingenus Pharmaceuticals Major Business
        2.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
        2.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
    2.7 Pfizer
        2.7.1 Pfizer Details
        2.7.2 Pfizer Major Business
        2.7.3 Pfizer Neuroblastoma Treatment Drugs Product and Services
        2.7.4 Pfizer Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 Pfizer Recent Developments/Updates
    2.8 Hikma Pharmaceuticals
        2.8.1 Hikma Pharmaceuticals Details
        2.8.2 Hikma Pharmaceuticals Major Business
        2.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
        2.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Hikma Pharmaceuticals Recent Developments/Updates
    2.9 Teva Pharmaceuticals
        2.9.1 Teva Pharmaceuticals Details
        2.9.2 Teva Pharmaceuticals Major Business
        2.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
        2.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 Teva Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Neuroblastoma Treatment Drugs by Manufacturer
    3.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2019-2024)
    3.3 Global Neuroblastoma Treatment Drugs Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Neuroblastoma Treatment Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2023
        3.4.2 Top 6 Neuroblastoma Treatment Drugs Manufacturer Market Share in 2023
    3.5 Neuroblastoma Treatment Drugs Market: Overall Company Footprint Analysis
        3.5.1 Neuroblastoma Treatment Drugs Market: Region Footprint
        3.5.2 Neuroblastoma Treatment Drugs Market: Company Product Type Footprint
        3.5.3 Neuroblastoma Treatment Drugs Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Neuroblastoma Treatment Drugs Market Size by Region
        4.1.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Region (2019-2030)
        4.1.2 Global Neuroblastoma Treatment Drugs Consumption Value by Region (2019-2030)
        4.1.3 Global Neuroblastoma Treatment Drugs Average Price by Region (2019-2030)
    4.2 North America Neuroblastoma Treatment Drugs Consumption Value (2019-2030)
    4.3 Europe Neuroblastoma Treatment Drugs Consumption Value (2019-2030)
    4.4 Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value (2019-2030)
    4.5 South America Neuroblastoma Treatment Drugs Consumption Value (2019-2030)
    4.6 Middle East and Africa Neuroblastoma Treatment Drugs Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2030)
    5.2 Global Neuroblastoma Treatment Drugs Consumption Value by Type (2019-2030)
    5.3 Global Neuroblastoma Treatment Drugs Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2030)
    6.2 Global Neuroblastoma Treatment Drugs Consumption Value by Application (2019-2030)
    6.3 Global Neuroblastoma Treatment Drugs Average Price by Application (2019-2030)

7 North America
    7.1 North America Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2030)
    7.2 North America Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2030)
    7.3 North America Neuroblastoma Treatment Drugs Market Size by Country
        7.3.1 North America Neuroblastoma Treatment Drugs Sales Quantity by Country (2019-2030)
        7.3.2 North America Neuroblastoma Treatment Drugs Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2030)
    8.2 Europe Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2030)
    8.3 Europe Neuroblastoma Treatment Drugs Market Size by Country
        8.3.1 Europe Neuroblastoma Treatment Drugs Sales Quantity by Country (2019-2030)
        8.3.2 Europe Neuroblastoma Treatment Drugs Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Neuroblastoma Treatment Drugs Market Size by Region
        9.3.1 Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2030)
    10.2 South America Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2030)
    10.3 South America Neuroblastoma Treatment Drugs Market Size by Country
        10.3.1 South America Neuroblastoma Treatment Drugs Sales Quantity by Country (2019-2030)
        10.3.2 South America Neuroblastoma Treatment Drugs Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Neuroblastoma Treatment Drugs Market Size by Country
        11.3.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Neuroblastoma Treatment Drugs Market Drivers
    12.2 Neuroblastoma Treatment Drugs Market Restraints
    12.3 Neuroblastoma Treatment Drugs Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Neuroblastoma Treatment Drugs and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Neuroblastoma Treatment Drugs
    13.3 Neuroblastoma Treatment Drugs Production Process
    13.4 Neuroblastoma Treatment Drugs Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Neuroblastoma Treatment Drugs Typical Distributors
    14.3 Neuroblastoma Treatment Drugs Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Neuroblastoma Treatment Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global Neuroblastoma Treatment Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. United Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 4. United Therapeutics Major Business
    Table 5. United Therapeutics Neuroblastoma Treatment Drugs Product and Services
    Table 6. United Therapeutics Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. United Therapeutics Recent Developments/Updates
    Table 8. Y-mAbs Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 9. Y-mAbs Therapeutics Major Business
    Table 10. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product and Services
    Table 11. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 12. Y-mAbs Therapeutics Recent Developments/Updates
    Table 13. EUSA Pharma Basic Information, Manufacturing Base and Competitors
    Table 14. EUSA Pharma Major Business
    Table 15. EUSA Pharma Neuroblastoma Treatment Drugs Product and Services
    Table 16. EUSA Pharma Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 17. EUSA Pharma Recent Developments/Updates
    Table 18. ANI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 19. ANI Pharmaceuticals Major Business
    Table 20. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
    Table 21. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 22. ANI Pharmaceuticals Recent Developments/Updates
    Table 23. Baxter Healthcare Basic Information, Manufacturing Base and Competitors
    Table 24. Baxter Healthcare Major Business
    Table 25. Baxter Healthcare Neuroblastoma Treatment Drugs Product and Services
    Table 26. Baxter Healthcare Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 27. Baxter Healthcare Recent Developments/Updates
    Table 28. Ingenus Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 29. Ingenus Pharmaceuticals Major Business
    Table 30. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
    Table 31. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 32. Ingenus Pharmaceuticals Recent Developments/Updates
    Table 33. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 34. Pfizer Major Business
    Table 35. Pfizer Neuroblastoma Treatment Drugs Product and Services
    Table 36. Pfizer Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 37. Pfizer Recent Developments/Updates
    Table 38. Hikma Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 39. Hikma Pharmaceuticals Major Business
    Table 40. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
    Table 41. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 42. Hikma Pharmaceuticals Recent Developments/Updates
    Table 43. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 44. Teva Pharmaceuticals Major Business
    Table 45. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product and Services
    Table 46. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 47. Teva Pharmaceuticals Recent Developments/Updates
    Table 48. Global Neuroblastoma Treatment Drugs Sales Quantity by Manufacturer (2019-2024) & (K Units)
    Table 49. Global Neuroblastoma Treatment Drugs Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 50. Global Neuroblastoma Treatment Drugs Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 51. Market Position of Manufacturers in Neuroblastoma Treatment Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 52. Head Office and Neuroblastoma Treatment Drugs Production Site of Key Manufacturer
    Table 53. Neuroblastoma Treatment Drugs Market: Company Product Type Footprint
    Table 54. Neuroblastoma Treatment Drugs Market: Company Product Application Footprint
    Table 55. Neuroblastoma Treatment Drugs New Market Entrants and Barriers to Market Entry
    Table 56. Neuroblastoma Treatment Drugs Mergers, Acquisition, Agreements, and Collaborations
    Table 57. Global Neuroblastoma Treatment Drugs Sales Quantity by Region (2019-2024) & (K Units)
    Table 58. Global Neuroblastoma Treatment Drugs Sales Quantity by Region (2025-2030) & (K Units)
    Table 59. Global Neuroblastoma Treatment Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 60. Global Neuroblastoma Treatment Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 61. Global Neuroblastoma Treatment Drugs Average Price by Region (2019-2024) & (US$/Unit)
    Table 62. Global Neuroblastoma Treatment Drugs Average Price by Region (2025-2030) & (US$/Unit)
    Table 63. Global Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 64. Global Neuroblastoma Treatment Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 65. Global Neuroblastoma Treatment Drugs Consumption Value by Type (2019-2024) & (USD Million)
    Table 66. Global Neuroblastoma Treatment Drugs Consumption Value by Type (2025-2030) & (USD Million)
    Table 67. Global Neuroblastoma Treatment Drugs Average Price by Type (2019-2024) & (US$/Unit)
    Table 68. Global Neuroblastoma Treatment Drugs Average Price by Type (2025-2030) & (US$/Unit)
    Table 69. Global Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 70. Global Neuroblastoma Treatment Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 71. Global Neuroblastoma Treatment Drugs Consumption Value by Application (2019-2024) & (USD Million)
    Table 72. Global Neuroblastoma Treatment Drugs Consumption Value by Application (2025-2030) & (USD Million)
    Table 73. Global Neuroblastoma Treatment Drugs Average Price by Application (2019-2024) & (US$/Unit)
    Table 74. Global Neuroblastoma Treatment Drugs Average Price by Application (2025-2030) & (US$/Unit)
    Table 75. North America Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 76. North America Neuroblastoma Treatment Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 77. North America Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 78. North America Neuroblastoma Treatment Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 79. North America Neuroblastoma Treatment Drugs Sales Quantity by Country (2019-2024) & (K Units)
    Table 80. North America Neuroblastoma Treatment Drugs Sales Quantity by Country (2025-2030) & (K Units)
    Table 81. North America Neuroblastoma Treatment Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 82. North America Neuroblastoma Treatment Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 83. Europe Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 84. Europe Neuroblastoma Treatment Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 85. Europe Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 86. Europe Neuroblastoma Treatment Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 87. Europe Neuroblastoma Treatment Drugs Sales Quantity by Country (2019-2024) & (K Units)
    Table 88. Europe Neuroblastoma Treatment Drugs Sales Quantity by Country (2025-2030) & (K Units)
    Table 89. Europe Neuroblastoma Treatment Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 90. Europe Neuroblastoma Treatment Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 91. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 92. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 93. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 94. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 95. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Region (2019-2024) & (K Units)
    Table 96. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity by Region (2025-2030) & (K Units)
    Table 97. Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 98. Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 99. South America Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 100. South America Neuroblastoma Treatment Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 101. South America Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 102. South America Neuroblastoma Treatment Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 103. South America Neuroblastoma Treatment Drugs Sales Quantity by Country (2019-2024) & (K Units)
    Table 104. South America Neuroblastoma Treatment Drugs Sales Quantity by Country (2025-2030) & (K Units)
    Table 105. South America Neuroblastoma Treatment Drugs Consumption Value by Country (2019-2024) & (USD Million)
    Table 106. South America Neuroblastoma Treatment Drugs Consumption Value by Country (2025-2030) & (USD Million)
    Table 107. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Type (2019-2024) & (K Units)
    Table 108. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Type (2025-2030) & (K Units)
    Table 109. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Application (2019-2024) & (K Units)
    Table 110. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Application (2025-2030) & (K Units)
    Table 111. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Region (2019-2024) & (K Units)
    Table 112. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity by Region (2025-2030) & (K Units)
    Table 113. Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value by Region (2019-2024) & (USD Million)
    Table 114. Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value by Region (2025-2030) & (USD Million)
    Table 115. Neuroblastoma Treatment Drugs Raw Material
    Table 116. Key Manufacturers of Neuroblastoma Treatment Drugs Raw Materials
    Table 117. Neuroblastoma Treatment Drugs Typical Distributors
    Table 118. Neuroblastoma Treatment Drugs Typical Customers
List of Figures
    Figure 1. Neuroblastoma Treatment Drugs Picture
    Figure 2. Global Neuroblastoma Treatment Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Type in 2023
    Figure 4. Cyclophosphamide Examples
    Figure 5. Dinutuximab Examples
    Figure 6. Naxitamab Examples
    Figure 7. Doxorubicin Hydrochloride Examples
    Figure 8. Vincristine Sulfate Examples
    Figure 9. Other Examples
    Figure 10. Global Neuroblastoma Treatment Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 11. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Application in 2023
    Figure 12. Hospital Examples
    Figure 13. Clinic Examples
    Figure 14. Other Examples
    Figure 15. Global Neuroblastoma Treatment Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 16. Global Neuroblastoma Treatment Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 17. Global Neuroblastoma Treatment Drugs Sales Quantity (2019-2030) & (K Units)
    Figure 18. Global Neuroblastoma Treatment Drugs Average Price (2019-2030) & (US$/Unit)
    Figure 19. Global Neuroblastoma Treatment Drugs Sales Quantity Market Share by Manufacturer in 2023
    Figure 20. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Manufacturer in 2023
    Figure 21. Producer Shipments of Neuroblastoma Treatment Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 22. Top 3 Neuroblastoma Treatment Drugs Manufacturer (Consumption Value) Market Share in 2023
    Figure 23. Top 6 Neuroblastoma Treatment Drugs Manufacturer (Consumption Value) Market Share in 2023
    Figure 24. Global Neuroblastoma Treatment Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 25. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 26. North America Neuroblastoma Treatment Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 27. Europe Neuroblastoma Treatment Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 28. Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 29. South America Neuroblastoma Treatment Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 30. Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value (2019-2030) & (USD Million)
    Figure 31. Global Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 32. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Type (2019-2030)
    Figure 33. Global Neuroblastoma Treatment Drugs Average Price by Type (2019-2030) & (US$/Unit)
    Figure 34. Global Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 35. Global Neuroblastoma Treatment Drugs Consumption Value Market Share by Application (2019-2030)
    Figure 36. Global Neuroblastoma Treatment Drugs Average Price by Application (2019-2030) & (US$/Unit)
    Figure 37. North America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 38. North America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 39. North America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 40. North America Neuroblastoma Treatment Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 41. United States Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 42. Canada Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 43. Mexico Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 44. Europe Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 45. Europe Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 46. Europe Neuroblastoma Treatment Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 47. Europe Neuroblastoma Treatment Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 48. Germany Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 49. France Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 50. United Kingdom Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 51. Russia Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 52. Italy Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 53. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 54. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 55. Asia-Pacific Neuroblastoma Treatment Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 56. Asia-Pacific Neuroblastoma Treatment Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 57. China Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 58. Japan Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 59. Korea Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 60. India Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 61. Southeast Asia Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 62. Australia Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 63. South America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 64. South America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 65. South America Neuroblastoma Treatment Drugs Sales Quantity Market Share by Country (2019-2030)
    Figure 66. South America Neuroblastoma Treatment Drugs Consumption Value Market Share by Country (2019-2030)
    Figure 67. Brazil Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 68. Argentina Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 69. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity Market Share by Type (2019-2030)
    Figure 70. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity Market Share by Application (2019-2030)
    Figure 71. Middle East & Africa Neuroblastoma Treatment Drugs Sales Quantity Market Share by Region (2019-2030)
    Figure 72. Middle East & Africa Neuroblastoma Treatment Drugs Consumption Value Market Share by Region (2019-2030)
    Figure 73. Turkey Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 74. Egypt Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 75. Saudi Arabia Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 76. South Africa Neuroblastoma Treatment Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 77. Neuroblastoma Treatment Drugs Market Drivers
    Figure 78. Neuroblastoma Treatment Drugs Market Restraints
    Figure 79. Neuroblastoma Treatment Drugs Market Trends
    Figure 80. Porters Five Forces Analysis
    Figure 81. Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs in 2023
    Figure 82. Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
    Figure 83. Neuroblastoma Treatment Drugs Industrial Chain
    Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 85. Direct Channel Pros & Cons
    Figure 86. Indirect Channel Pros & Cons
    Figure 87. Methodology
    Figure 88. Research Process and Data Source

Companies Mentioned

United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals